APUNTES DE CIENCIA - hgucr

A R T Í C U L O E S P E C I A L
44. Baker M, Gillanders WE, Mikhitarian K, Mitas M, Cole D.
The molecular detection of micrometastatic breast cancer.
Am J Surg. 2003;186:351-8.
45. Lianidou ES, Markou A. Circulating tumor cells in breast
cancer: detection systems, molecular characterization, and
future challenges. Clin Chem. 2011 Sep;57(9):1242-55.
46. Houghton RL, Dillon DC, Molesh DA, Zehentner BK, Xu J,
Jiang J, et al. Transcriptional complementarity in breast
cancer: application to detection of circulating tumor cells.
Mol Diagn. 2001;6:79-91.
47. Sieuwerts AM, Kraan J, Bolt-de Vries J, van der Spoel P,
Mostert B, Martens JW, et al. Molecular characterization of
circulating tumor cells in large quantities of contaminating
leukocytes by a multiplex real-time PCR. Breast Cancer Res
Treat. 2009 Dec;118(3):455-68.
48. Alix-Panabières C, Riethdorf S, Pantel K. Circulating
tumor cells and bone marrow micrometastasis. Clin Cancer
Res 2008; 14: 5013–5021.
49. Bernards R, Weinberg RA. A progression puzzle. Nature
2002; 418: 823.
50. Gradilone A, Naso G, Raimondi C, Cortesi E, Gandini O,
Vincenzi B, et al. Circulating tumor cells (CTCs) in metastatic
breast cancer (MBC): prognosis, drug resistance and
phenotypic characterization. Ann Oncol. 2011 Jan;22(1):86-
92.
51. Ignatiadis M, Georgoulias V, Mavroudis D.
Micrometastatic disease in breast cancer: Clinical
implications. European journal of cancer 2008; 44: 2726-36.
52. Stathopoulou A, Gizi A, Perraki M, Apostolaki S,
Malamos N, Mavroudis D, et al. Real-time quantification of
CK-19 mRNA-positive cells in peripheral blood of breast
cancer patients using the lightcycler system. Clin. Cancer
Res. 9 (14) (2003) 5145–5151.
53. Daskalaki A, Agelaki S, Perraki M, Apostolaki S, Xenidis
N, Stathopoulos E, et al. Detection of cytokeratin-19 mRNApositive
cells in the peripheral blood and bone marrow of
patients with operable breast cancer. Br J Cancer 2009;
101:589-97.
54. Xenidis N, Apostolaki S, Perraki M. Circulating CK-19
mRNA (+) cells in patients with stage I and II breast cancer
after the completion of adjuvant chemotherapy: evaluation of
their prognostic relevance. Breast Cancer Res Treat
2007;106(Suppl. 1) [abstract 109].
55. Brabletz T, Jung A, Spaderna S, Hlubek F, Kirchner T.
Opinion: migrating cancer stem cells – an integrated concept
of malignant tumour progression. Nat Rev Cancer
2005;5:744–9.
56. Gazzaniga P, Gradilone A, Naso G, Cortesi E, Gianni W,
Frati L, et al. Chemoresistance profile of circulating tumor
cells: toward a clinical benefit? Int J Cancer 2008; 123:
1730–1732.
57. Gazzaniga P, Naso G, Gradilone A, Cortesi E, Gandini O,
Gianni W, et al. Chemosensitivity profile assay of circulating
cancer cells (CTCs): prognostic and predictive value in
epithelial tumors. Int J Cancer 2010; 126(10): 2437–2447.
58. de Cremoux P, Extra JM, Denis MG, Pierga JY, Bourstyn E,
Nos C, et al. Detection of MUC1- expressing mammary
carcinoma cells in the peripheral blood of breast cancer
patients by real-time polymerase chain reaction. Clin Cancer
Res 2000;6:3117–22.
59. Zach O, Kasparu H, Wagner H, Krieger O, Lutz D.
Prognostic value of tumour cell detection in peripheral blood
of breast cancer patients. Acta Med Austriaca Suppl
2002;59:32–4.
60. Silva AL, Tome MJ, Correia AE, Passos-Coelho JL.
Human mammaglobin RT-PCR assay for detection of occult
breast cancer cells in hematopoietic products. Ann Oncol
2002;13:422–9.
61. Ntoulia M, Stathopoulou A, Ignatiadis M, Malamos N,
Mavroudis D, Georgoulias V, et al. Detection of mammaglobin
A-mRNA-positive circulating tumor cells in peripheral blood
of patients with operable breast cancer with nested RT-PCR.
Clin Biochem 2006;39:879–87.
18 Apunt. Cienc. 2011 VOL 1(4)